Annals of Oncology最新文献

{"title":"Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008☆","authors":"S.Y. Ryu ,&nbsp;W. Deng ,&nbsp;K. Albuquerque ,&nbsp;W.-J. Koh ,&nbsp;J. Mayadev ,&nbsp;A. Heugel ,&nbsp;B.-J. Kim ,&nbsp;D.-Y. Kim ,&nbsp;C.-H. Cho ,&nbsp;J.-W. Kim ,&nbsp;J.H. No ,&nbsp;R.S. Mannel ,&nbsp;K. Miller ,&nbsp;D. Fabian ,&nbsp;D.M. Chase ,&nbsp;K.M. Gil ,&nbsp;W. Small Jr. ,&nbsp;W. Rodgers ,&nbsp;C.A. Leath III ,&nbsp;B.J. Monk","doi":"10.1016/j.annonc.2025.09.003","DOIUrl":"10.1016/j.annonc.2025.09.003","url":null,"abstract":"<div><h3>Background</h3><div>To determine whether adjuvant chemoradiation (CRT) with weekly cisplatin improves recurrence-free survival (RFS) compared with radiation (RT) in pathologically proven intermediate risk early-stage cervical cancer following radical hysterectomy and lymphadenectomy.</div></div><div><h3>Methods</h3><div>Post-surgical patients with stage I-IIA cervical cancer with pathologically noted intermediate risk factors including combinations of capillary lymphatic space involvement, stromal invasion, and tumor size were randomly assigned in a 1 : 1 ratio to receive either adjuvant CRT or RT (NCT01101451). Patients received conformal RT, or intensity modulated radiation therapy. In the CRT arm, 6 weekly cycles of cisplatin 40 mg/m² were administered during RT. RFS was the primary endpoint in randomized and eligible patients. Secondary endpoints included overall survival (OS), quality of life (QoL), and adverse events (AEs).</div></div><div><h3>Results</h3><div>Of the 340 randomized patients, 316 were eligible and most had Federation of Gynecology and Obstetrics (2009) stage IB₁ and squamous cell carcinoma histology. Out of 316 patients, 292 (92.4%) received 28 fractions of RT with a median dose of 50.4 Gy and a median treatment duration of 39 days. Three-year RFS was 88.5% in the CRT arm and 85.4% in the RT arm. Both RFS [hazard ratio (HR) 0.698, 95% confidence interval (CI) 0.408-1.192, <em>P</em> = 0.09], as well as OS [HR 0.586, 95% CI 0.286-1.199, <em>P</em> = 0.07] favored CRT compared with RT alone. Grade 3 or 4 AEs occurred in 43% and 15% in the CRT and RT arms, respectively (<em>P</em> &lt; 0.01). A transient decline in QoL occurred in the CRT arm compared with RT after starting treatments and recovered to pre-treatment level by 36 weeks.</div></div><div><h3>Conclusion</h3><div>Although RFS and OS favored CRT, the addition of cisplatin during RT did not statistically improve RFS or OS in cervical cancer patients with intermediate pathological risk factors following radical hysterectomy and lymphadenectomy. CRT increased grade 3 and 4 AEs with a transient decline in QoL.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 12","pages":"Pages 1514-1524"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"42eP Digital twin approach for AI-based prediction of neoadjuvant therapy response in HER2-positive breast cancer","authors":"C-H. Chen ,&nbsp;I-C. Tsai","doi":"10.1016/j.annonc.2025.10.876","DOIUrl":"10.1016/j.annonc.2025.10.876","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1777"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"43eP Risk of axillary nodal metastasis in HER2-positive and triple-negative breast cancer: Exploration for omission of sentinel lymph node biopsy","authors":"K-T. Hwang","doi":"10.1016/j.annonc.2025.10.877","DOIUrl":"10.1016/j.annonc.2025.10.877","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1777"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"38P The impact of aerobic and resistance exercise intervention for 12 weeks on interleukin-6, interleukin-10, cancer-related fatigue, and metabolic equivalent of task in patients with hormone receptor-positive breast cancer stage I-III at RSUP Dr. Sardjito, Yogyakarta","authors":"M.D.L.Q. Mozhaf ,&nbsp;Y. Kartika Astari ,&nbsp;S.H. Hutajulu ,&nbsp;D.K. Paramita ,&nbsp;A.B. Hartopo ,&nbsp;M.S. Hardianti ,&nbsp;K. Widayati ,&nbsp;J. Kurnianda ,&nbsp;I. Purwanto","doi":"10.1016/j.annonc.2025.10.872","DOIUrl":"10.1016/j.annonc.2025.10.872","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Pages S1775-S1776"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial☆","authors":"J. Xu ,&nbsp;J. Chen ,&nbsp;S. Song ,&nbsp;L. Song ,&nbsp;R. Wang ,&nbsp;J. Hao ,&nbsp;X. Du ,&nbsp;D. Cao ,&nbsp;Y. Gao ,&nbsp;X. Lan ,&nbsp;A. Yang ,&nbsp;W. Miao ,&nbsp;H. Xu ,&nbsp;Y. Chen ,&nbsp;L. Li ,&nbsp;H. Shi ,&nbsp;X. Yuan ,&nbsp;F. Ye ,&nbsp;J. Wang ,&nbsp;N. Xu ,&nbsp;P. Wang","doi":"10.1016/j.annonc.2025.08.3758","DOIUrl":"10.1016/j.annonc.2025.08.3758","url":null,"abstract":"<div><h3>Background</h3><div>The phase III trial, XT-XTR008-3-01, was a randomised controlled trial (RCT) that evaluated the efficacy and safety of XTR008, a novel no-carrier-added lutetium-177 (¹⁷⁷Lu)–Dotatate, for the first time in a later-line therapy setting for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of all origins.</div></div><div><h3>Patients and methods</h3><div>Patients with grade 1-2, unresectable, locally advanced or metastatic GEP-NETs who had progressed within the last 12 months before randomisation were randomly allocated 1 : 1 to XTR008 (four cycles every 8 weeks) or octreotide 60 mg (every 4 weeks), stratified by primary tumour site (pancreatic versus non-pancreatic), pathological tumour grade (1 versus 2), and duration of prior somatostatin analogues treatment (≤6 versus &gt;6 months). The primary endpoint was progression-free survival (PFS) by a blinded independent review committee. The key secondary endpoints included overall response rate (ORR); overall survival (OS); quality of life, evaluated using the European Organisation for Research and Treatment of Cancer quality of life questionnaires QLQ-C30 and QLQ-GI.NET21; safety; pharmacokinetics; and dosimetry.</div></div><div><h3>Results</h3><div>Patients (<em>N =</em> 196) were randomized to XTR008 (<em>n</em> = 99) or control (<em>n</em> = 97). Primary tumour sites: pancreas (59%), rectum (28%), midgut (7%). Median follow-up: 11.1 months [interquartile range (IQR) 8.5-11.5, XTR008] versus 10.2 months (IQR 8.5-11.9 months, control). With 78 PFS events, median PFS was not reached [95% confidence interval (CI) 16.13 months to not estimated] versus 5.8 months (95% CI 5.65-8.41 months); stratified hazard ratio (HR) 0.06 (<em>P</em> &lt; 0.0001). ORR: 43.4% (95% CI 33.50% to 53.77%) versus 1.0% (95% CI 0.03% to 5.61%). OS data were immature for both groups, with XTR008 showing a longer survival trend (HR 0.24, <em>P</em> = 0.0550). Treatment-related adverse events: 98% versus 89%; serious adverse events: 16.3% versus 12.5% (6.1% versus 3.1% drug-related). Myelodysplastic syndrome and grade ≥3 renal toxicity occurred in 1% of patients in the XTR008 group; no acute myeloid leukaemia or drug-related deaths occurred.</div></div><div><h3>Conclusions</h3><div>XTR008 monotherapy showed superior efficacy versus high-dose long-acting repeatable (LAR) octreotide monotherapy in advanced GEP-NET tumours of all origins in a later-line treatment setting, with manageable safety, supporting its use as a new treatment option.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 12","pages":"Pages 1458-1467"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LBA1 Analysis of Asian patients (pts) with HR+/HER2− early breast cancer (EBC) treated with ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI): 5-year outcomes from NATALEE","authors":"Y-S. Lu ,&nbsp;D.L. Stroyakovskiy ,&nbsp;J. Sohn ,&nbsp;Y.H. Park ,&nbsp;C-S. Huang ,&nbsp;S-A. Im ,&nbsp;K.H. Jung ,&nbsp;A. Chan ,&nbsp;J. Zhang ,&nbsp;J. Lee ,&nbsp;J.H. Kim ,&nbsp;C-F. Chung ,&nbsp;D. Slamon ,&nbsp;V. Sakalosh ,&nbsp;M. Gao ,&nbsp;K. Amin ,&nbsp;N. Harun ,&nbsp;B. Xu","doi":"10.1016/j.annonc.2025.10.834","DOIUrl":"10.1016/j.annonc.2025.10.834","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1765"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3MO Axillary management strategies in breast cancer patients with ypN0 after neoadjuvant therapy","authors":"Q. Shang ,&nbsp;Y. Zhuang ,&nbsp;S. Luo ,&nbsp;X. Wang","doi":"10.1016/j.annonc.2025.10.837","DOIUrl":"10.1016/j.annonc.2025.10.837","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1766"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"12P TIME-TNBC: A landmark-based dynamic prediction model for patients with triple-negative breast cancer","authors":"Q. Shang ,&nbsp;K. Xu ,&nbsp;S. Luo ,&nbsp;X. Wang","doi":"10.1016/j.annonc.2025.10.846","DOIUrl":"10.1016/j.annonc.2025.10.846","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Pages S1768-S1769"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"47eP Clinicopathologic characteristics of HER2-low localized breast cancer in Tunisia: A comparative study of HER2 1+ and HER2 2+/FISH-negative subgroups","authors":"W. Ben Kridis ,&nbsp;C. Belfekih Hassen ,&nbsp;I. Hammouda ,&nbsp;N. Toumi ,&nbsp;K. Chaabene ,&nbsp;T. Boudawara ,&nbsp;J. Daoud ,&nbsp;A. Khanfir","doi":"10.1016/j.annonc.2025.10.881","DOIUrl":"10.1016/j.annonc.2025.10.881","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1778"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"87MO Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer: The CAPItello-290 phase III trial extended China cohort","authors":"W. Xia ,&nbsp;S. Wang ,&nbsp;J. Yang ,&nbsp;T. Luo ,&nbsp;H. Wang ,&nbsp;X. Wang ,&nbsp;Y. Wang ,&nbsp;Y. Yin ,&nbsp;J. Ou ,&nbsp;H. Wang ,&nbsp;W. Li ,&nbsp;O. Wang ,&nbsp;S. Wang ,&nbsp;J. Luo ,&nbsp;H. Xiong ,&nbsp;W. Zhao ,&nbsp;L. Jiang ,&nbsp;K. Laskowska-Macios ,&nbsp;P. Schmid ,&nbsp;B. Xu","doi":"10.1016/j.annonc.2025.10.922","DOIUrl":"10.1016/j.annonc.2025.10.922","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Pages S1787-S1788"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}